Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Immunotherapy of melanoma: an update.

Homsi J, Grimm JC, Hwu P.

Surg Oncol Clin N Am. 2011 Jan;20(1):145-63. doi: 10.1016/j.soc.2010.09.004. Review.

PMID:
21111964
2.

Immunotherapy: Vaccine trials in melanoma -- time for reflection.

Eggermont AM.

Nat Rev Clin Oncol. 2009 May;6(5):256-8. doi: 10.1038/nrclinonc.2009.42.

PMID:
19390551
3.
4.

[Are immunological treatments beneficial for malignant melanoma of the skin?].

Vihinen P, Vuoristo MS, Hernberg M, Pyrhönen S.

Duodecim. 2010;126(14):1701-10. Review. Finnish.

PMID:
20804089
5.

Update on immunotherapy for melanoma.

Ribas A.

J Natl Compr Canc Netw. 2006 Aug;4(7):687-94. Review.

PMID:
16884670
6.

Immunotherapy of melanoma.

Parmiani G, Castelli C, Rivoltini L, Casati C, Tully GA, Novellino L, Patuzzo A, Tosi D, Anichini A, Santinami M.

Semin Cancer Biol. 2003 Dec;13(6):391-400. Review.

PMID:
15001157
7.

Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.

Kalani AD, Jack A, Montenegro G, Degliuomini J, Wallack MK.

G Ital Dermatol Venereol. 2008 Feb;143(1):59-70. Review.

PMID:
18833052
8.

Melanoma immunotherapy: historical precedents, recent successes and future prospects.

Raaijmakers MI, Rozati S, Goldinger SM, Widmer DS, Dummer R, Levesque MP.

Immunotherapy. 2013 Feb;5(2):169-82. doi: 10.2217/imt.12.162. Review.

PMID:
23413908
9.

Next generation of immunotherapy for melanoma.

Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ.

J Clin Oncol. 2008 Jul 10;26(20):3445-55. doi: 10.1200/JCO.2007.14.6423. Review.

PMID:
18612161
10.

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.

Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE.

J Clin Oncol. 2007 May 20;25(15):2078-85.

11.

Immunotherapy for melanoma.

Kim CJ, Dessureault S, Gabrilovich D, Reintgen DS, Slingluff CL Jr.

Cancer Control. 2002 Jan-Feb;9(1):22-30. Review.

12.

Does adjuvant vaccine therapy really have activity in malignant melanoma?

Wheatley K, Ives NJ, Lorigan P.

J Clin Oncol. 2007 Oct 10;25(29):4693; author reply 4693-5. No abstract available.

13.
14.

Diagnosis and management of malignant melanoma.

Goldstein BG, Goldstein AO.

Am Fam Physician. 2001 Apr 1;63(7):1359-68, 1374. Review. Erratum in: Am Fam Physician 2001 Nov 15;64(10):1682.

15.

Recent advances and hurdles in melanoma immunotherapy.

Jandus C, Speiser D, Romero P.

Pigment Cell Melanoma Res. 2009 Dec;22(6):711-23. doi: 10.1111/j.1755-148X.2009.00634.x. Epub 2009 Sep 7. Review.

PMID:
19735459
16.
17.

Immunotherapy and experimental approaches for metastatic melanoma.

Atkins MB.

Hematol Oncol Clin North Am. 1998 Aug;12(4):877-902, viii. Review.

PMID:
9759585
18.

Melanoma: is immunotherapy of benefit?

Faries MB, Morton DL.

Adv Surg. 2003;37:139-69. Review. No abstract available.

PMID:
12953631
19.

Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.

Speiser DE, Pittet MJ, Rimoldi D, Guillaume P, Luescher IF, Liénard D, Lejeune F, Cerottini JC, Romero P.

Semin Cancer Biol. 2003 Dec;13(6):461-72. Review.

PMID:
15001165
20.

Melanoma immunotherapy.

Sivendran S, Glodny B, Pan M, Merad M, Saenger Y.

Mt Sinai J Med. 2010 Nov-Dec;77(6):620-42. doi: 10.1002/msj.20215. Review.

PMID:
21105125
Items per page

Supplemental Content

Write to the Help Desk